Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.
Publication
, Journal Article
Jacoby, D; Ho, CY; Lester, SJ; Wang, A; Olivotto, I
Published in: Lancet
January 30, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 30, 2021
Volume
397
Issue
10272
Start / End Page
369 / 370
Location
England
Related Subject Headings
- Uracil
- Humans
- General & Internal Medicine
- Cardiomyopathy, Hypertrophic
- Benzylamines
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jacoby, D., Ho, C. Y., Lester, S. J., Wang, A., & Olivotto, I. (2021). Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. Lancet, 397(10272), 369–370. https://doi.org/10.1016/S0140-6736(20)32391-6
Jacoby, Daniel, Carolyn Y. Ho, Steven J. Lester, Andrew Wang, and Iacopo Olivotto. “Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.” Lancet 397, no. 10272 (January 30, 2021): 369–70. https://doi.org/10.1016/S0140-6736(20)32391-6.
Jacoby D, Ho CY, Lester SJ, Wang A, Olivotto I. Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. Lancet. 2021 Jan 30;397(10272):369–70.
Jacoby, Daniel, et al. “Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.” Lancet, vol. 397, no. 10272, Jan. 2021, pp. 369–70. Pubmed, doi:10.1016/S0140-6736(20)32391-6.
Jacoby D, Ho CY, Lester SJ, Wang A, Olivotto I. Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. Lancet. 2021 Jan 30;397(10272):369–370.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 30, 2021
Volume
397
Issue
10272
Start / End Page
369 / 370
Location
England
Related Subject Headings
- Uracil
- Humans
- General & Internal Medicine
- Cardiomyopathy, Hypertrophic
- Benzylamines
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences